eukemia in chronic phase. J Clin Oncol. 2009, 27:4204�?0. 68. Burke AC, Swords RT, Kelly K, Giles FJ. Current status of agents active against the T315I chronic myeloid leukemia phenotype. Expert Opin Emerg Drugs. 2011, 16:85�?03. 69. Mahon FX, Rea D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid Estrogen Receptor Pathway leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib trial. Lancet Oncol. 2010, 11:1029�?5. 70. Deininger M. Hematology: curing CML with imatinib–a dream come true? Nat Rev Clin Oncol. 2011, 8:127�?. 71. Corbin AS, Agarwal A, Loriaux M, Cortes J, Deininger MW, Druker BJ. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J Clin Invest.
2011, 121:396�?09. 72. Giles FJ, Rosti G, Beris P, et al. Nilotinib is superior to imatinib as first-line therapy of chronic myeloid leukemia: the ENESTnd study. Expert Rev Hematol. 2010, 3:665�?3. 73. Mauro MJ, Deininger MW. Management of drug toxicities in chronic myeloid leukaemia. Best Pract Res Clin Haematol. 2009, 22:409�?9. 74. Gambacorti-Passerini Alvocidib 146426-40-6 C, Antolini L, Mahon FX, et al. Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J Natl Cancer Inst. 2011, 103:553�?1. 75. Boschelli DH, Ye F, Wang YD, et al. Optimization of 4-phenylamino-3-quinolinecarbonitriles as potent inhibitors of Src kinase activity. J Med Chem. 2001, 44:3965�?7. 76. Puttini M, Coluccia AM, Boschelli F, et al.
In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells. Cancer Res. 2006, 66:11314�?2. 77. Redaelli S, Piazza R, Rostagno R, et al. Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants. J Clin Oncol. 2009, 27:469�?1. 78. Huang WS, Metcalf CA, Sundaramoorthi R, et al. Discovery of 3- -4-methyl-N-{4- -3-Woessner et al. Page 13 Cancer J. Author manuscript, available in PMC 2012 May 1. NIH-PA Author Manuscript NIH-PA Author Manuscript NIH-PA Author Manuscript phenyl}benzamide , a potent, orally active pan-inhibitor of breakpoint cluster region-abelson kinase including the T315I gatekeeper mutant. J Med Chem. 2010, 53:4701�?9. 79. O,Hare T, Shakespeare WC, Zhu X, et al.
AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell. 2009, 16:401�?2. 80. Gozgit JM, Wong MJ, Wardwell S, et al. Potent Activity of Ponatinib in Models of FLT3-Driven Acute Myeloid Leukemia and Other Hematologic Malignancies. Mol Cancer Ther. 2011, 10:1028�?5. 81. Cortes J, Talpaz M, Bixby D, et al. A Phase 1 Trial of Oral Ponatinib In Patients with Refractory Chronic Myelogenous Leukemia and Other Hematologic Malignancies: Emerging Safety and Clinical Response Findings. ASH Annual Meeting Abstracts. 2010, 116:210. 82. Carmena M, Earnshaw WC. The cellular geography of aurora kinases. Nat Rev Mol Cell Biol. 2003, 4:842�?4. 83. Howard S, Berdini V, Boulstridge JA, et al. Fragment-based discovery of the pyrazol-4-yl urea , a multitargeted kinase inhibitor with potent aurora kinase activity.
J Med Chem. 2009, 52:379�?8. 84. Tanaka R, Squires MS, Kimura S, et al. Activity of the multitargeted kinase inhibitor, AT9283, in imatinib-resistant BCR-ABL-positive leukemic cells. Blood. 2010, 116:2089�?5. 85. Balabanov S, Gontarewicz A, Keller G, et al. Abcg2 overexpression represents a novel mechanism for acquired resistance to the multi-kinase inhibitor Danusertib in BCR-ABL-positive cells in vitro. PLoS One. 2011, 6:e19164. 86. Vertex,s Collaborator Merck Suspends Patient Enrollment in Clinical Trials of MK